Royalty Pharma (NASDAQ:RPRX) Hits New 12-Month Low at $28.22

Royalty Pharma plc (NASDAQ:RPRX) shares reached a new 52-week low on Friday . The stock traded as low as $28.22 and last traded at $28.28, with a volume of 336672 shares. The stock had previously closed at $28.76.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on RPRX shares. Morgan Stanley boosted their target price on shares of Royalty Pharma from $52.00 to $53.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 9th. StockNews.com started coverage on shares of Royalty Pharma in a research report on Thursday, August 17th. They issued a “hold” rating for the company. Finally, TheStreet raised shares of Royalty Pharma from a “d+” rating to a “c” rating in a research report on Thursday, June 15th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $53.25.

Royalty Pharma Price Performance

The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.52 and a current ratio of 2.52. The business’s 50 day simple moving average is $30.21 and its 200-day simple moving average is $32.65. The stock has a market capitalization of $16.93 billion, a price-to-earnings ratio of 65.42, a price-to-earnings-growth ratio of 1.46 and a beta of 0.39.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported $0.85 earnings per share for the quarter, topping analysts’ consensus estimates of $0.83 by $0.02. The company had revenue of $545.00 million during the quarter, compared to analyst estimates of $538.52 million. Royalty Pharma had a net margin of 10.84% and a return on equity of 29.03%. Research analysts anticipate that Royalty Pharma plc will post 4.18 earnings per share for the current year.

Royalty Pharma Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, September 15th. Investors of record on Friday, August 18th were issued a $0.20 dividend. The ex-dividend date was Thursday, August 17th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 2.84%. Royalty Pharma’s payout ratio is currently 186.05%.

Insider Buying and Selling

In related news, CFO Terrance P. Coyne sold 37,500 shares of the business’s stock in a transaction that occurred on Wednesday, August 9th. The shares were sold at an average price of $30.72, for a total value of $1,152,000.00. Following the sale, the chief financial officer now directly owns 827,500 shares in the company, valued at approximately $25,420,800. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Pablo G. Legorreta purchased 130,000 shares of the business’s stock in a transaction dated Wednesday, June 28th. The shares were acquired at an average price of $29.51 per share, for a total transaction of $3,836,300.00. Following the completion of the acquisition, the chief executive officer now directly owns 600,000 shares of the company’s stock, valued at $17,706,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Terrance P. Coyne sold 37,500 shares of the business’s stock in a transaction that occurred on Wednesday, August 9th. The shares were sold at an average price of $30.72, for a total transaction of $1,152,000.00. Following the sale, the chief financial officer now owns 827,500 shares in the company, valued at approximately $25,420,800. The disclosure for this sale can be found here. Insiders own 18.72% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. M&T Bank Corp increased its stake in Royalty Pharma by 2.5% in the 3rd quarter. M&T Bank Corp now owns 10,671 shares of the biopharmaceutical company’s stock valued at $428,000 after buying an additional 259 shares during the period. Argent Trust Co grew its position in Royalty Pharma by 3.6% in the fourth quarter. Argent Trust Co now owns 8,568 shares of the biopharmaceutical company’s stock worth $339,000 after acquiring an additional 300 shares in the last quarter. Sectoral Asset Management Inc. grew its position in Royalty Pharma by 2.5% in the fourth quarter. Sectoral Asset Management Inc. now owns 12,440 shares of the biopharmaceutical company’s stock worth $492,000 after acquiring an additional 300 shares in the last quarter. PNC Financial Services Group Inc. grew its position in Royalty Pharma by 7.3% in the second quarter. PNC Financial Services Group Inc. now owns 4,973 shares of the biopharmaceutical company’s stock worth $153,000 after acquiring an additional 337 shares in the last quarter. Finally, Guggenheim Capital LLC grew its position in Royalty Pharma by 0.3% in the second quarter. Guggenheim Capital LLC now owns 111,209 shares of the biopharmaceutical company’s stock worth $3,419,000 after acquiring an additional 355 shares in the last quarter. Institutional investors and hedge funds own 49.03% of the company’s stock.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.